Synonym
Foxy-5; Foxy 5; Foxy5; N-Formyl-Met-Asp-Gly-Cys-Glu-Leu
IUPAC/Chemical Name
(2S,5S,8R,14S)-5-(2-carboxyethyl)-14-((S)-2-formamido-4-(methylthio)butanamido)-2-isobutyl-8-(mercaptomethyl)-4,7,10,13-tetraoxo-3,6,9,12-tetraazahexadecanedioic acid
InChi Key
WFZPJYYCTSHDJI-ATIWLJMLSA-N
InChi Code
InChI=1S/C26H42N6O12S2/c1-13(2)8-17(26(43)44)32-24(41)15(4-5-20(35)36)30-25(42)18(11-45)29-19(34)10-27-22(39)16(9-21(37)38)31-23(40)14(28-12-33)6-7-46-3/h12-18,45H,4-11H2,1-3H3,(H,27,39)(H,28,33)(H,29,34)(H,30,42)(H,31,40)(H,32,41)(H,35,36)(H,37,38)(H,43,44)/t14-,15-,16-,17-,18-/m0/s1
SMILES Code
CC(C)C[C@@H](C(O)=O)NC([C@H](CCC(O)=O)NC([C@H](CS)NC(CNC([C@H](CC(O)=O)NC([C@H](CCSC)NC=O)=O)=O)=O)=O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
694.77
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Ford CE, Ekström EJ, Howlin J, Andersson T. The WNT-5a derived peptide, Foxy-5, possesses dual properties that impair progression of ERalpha negative breast cancer. Cell Cycle. 2009 Jun 15;8(12):1838-42. Review. Retraction in: Andersson T, Ford CE, Ekström EJ, Howlin J. Cell Cycle. 2011 Apr 1;10(7):1167. PubMed PMID: 19448401.
2: Säfholm A, Tuomela J, Rosenkvist J, Dejmek J, Härkönen P, Andersson T. The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin Cancer Res. 2008 Oct 15;14(20):6556-63. doi: 10.1158/1078-0432.CCR-08-0711. PubMed PMID: 18927296.
3: Andersson T, Ford CE, Ekström EJ, Howlin J. Retracted manuscript: The WNT-5a derived peptide, Foxy-5, possesses dual properties that impair progression of ERα negative breast cancer. Cell Cycle. 2011 Apr 1;10(7):1167. PubMed PMID: 21430443.
4: Mehdawi LM, Prasad CP, Ehrnström R, Andersson T, Sjölander A. Non-canonical WNT5A signaling up-regulates the expression of the tumor suppressor 15-PGDH and induces differentiation of colon cancer cells. Mol Oncol. 2016 Nov;10(9):1415-1429. doi: 10.1016/j.molonc.2016.07.011. PubMed PMID: 27522468.
5: Varela-Nallar L, Parodi J, Farías GG, Inestrosa NC. Wnt-5a is a synaptogenic factor with neuroprotective properties against Aβ toxicity. Neurodegener Dis. 2012;10(1-4):23-6. doi: 10.1159/000333360. Review. PubMed PMID: 22261402.
6: Ford CE, Ekström EJ, Andersson T. Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells. Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3919-24. doi: 10.1073/pnas.0809516106. Retraction in: Ford CE, Ekström EJ, Anderson T. Proc Natl Acad Sci U S A. 2010 Dec 21;107(51):22360. PubMed PMID: 19237581; PubMed Central PMCID: PMC2656180.
7: Compton DM, Dietrich KL, Selinger MC, Testa EK. 5-methoxy-N,N-di(iso)propyltryptamine hydrochloride (Foxy)-induced cognitive deficits in rat after exposure in adolescence. Physiol Behav. 2011 May 3;103(2):203-9. doi: 10.1016/j.physbeh.2011.01.021. PubMed PMID: 21295050.
